NCT03460977 2026-03-13A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPfizerPhase 1 Recruiting453 enrolled
NCT04067336 2025-11-10First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1/2 Recruiting263 enrolled 1 FDA
NCT02875223 2025-04-20A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's LymphomasCelgenePhase 1 Terminated75 enrolled 35 charts
NCT04537715 2025-02-19Effects of Itraconazole and Rifampin on the Blood Tazemetostat LevelsIpsenPhase 1 Completed42 enrolled 39 charts
NCT05602597 2024-03-06HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPIHutchmedPhase 1 Completed59 enrolled
NCT05720767 2023-03-01HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer StudyHutchmedPhase 1 Completed28 enrolled
NCT02253420 2020-12-14COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma PatientsBayerPhase 1 Completed51 enrolled
NCT02259010 2019-09-20A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory LymphomaTakedaPhase 1 Completed24 enrolled 26 charts
NCT00003883 2010-04-02Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow TransplantationFred Hutchinson Cancer CenterPhase 3 Completed578 enrolled